Celldex Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing antibody-based therapeutics in immunology and mast cell-mediated disease. Its 8-K reports furnish financial results and corporate updates, including clinical and regulatory disclosures for barzolvolimab programs and other pipeline candidates, as well as material-event and capital-structure disclosures related to common stock financing.
Proxy materials describe annual stockholder voting matters, director elections, auditor ratification, executive compensation and equity incentive plan proposals. The filing record also identifies Celldex common stock, par value $.001, trading under CLDX on the Nasdaq Capital Market.
Celldex Therapeutics, Inc. (CLDX) Schedule 13G amendment lists beneficial ownership of 8,411,905 shares, or 10.7% of the class, in the ownership entries for FMR LLC and reporting person Abigail P. Johnson. FMR LLC reported sole voting power over 8,396,651 shares and sole dispositive power over 8,411,905 shares; Johnson reported zero sole voting power and sole dispositive power over 8,411,905 shares. Both entries show zero shared voting and dispositive power. The amendment states that one or more other persons are known to have rights to dividends or sale proceeds, while no other person's interest exceeds 5% of the outstanding common stock.
Celldex Therapeutics, Inc. (CLDX) reported positive topline results from its two global Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of barzolvolimab in chronic spontaneous urticaria patients inadequately controlled by H1‑antihistamines. Both trials met the primary endpoint of mean change from baseline in weekly urticaria activity score (UAS7) at Week 12, and all key secondary endpoints, with clinically meaningful and statistically significant improvements versus placebo. In EMBARQ‑CSU1, barzolvolimab 150 mg every 4 weeks produced a least-squares mean UAS7 change of −20.2 at Week 12 from a baseline of 30.6, compared with −10.7 on placebo from a baseline of 30.9. Complete response (UAS7=0) at Week 12 reached 42.4% on 150 mg in EMBARQ‑CSU1 versus 9.3% on placebo, and 55.3% in omalizumab‑refractory patients on 150 mg. Barzolvolimab was reported as well‑tolerated through the 24‑week placebo‑controlled period with a safety profile consistent with prior Phase 2 data. Celldex plans to submit a Biologics License Application for barzolvolimab in CSU in 2027.
Kynam Capital Management, LP, together with Kynam Capital Management GP, LLC and Yue Tang, reports beneficial ownership of Celldex Therapeutics, Inc. common stock. The group has shared voting and dispositive power over 5,322,908 shares, representing 6.78% of Celldex’s outstanding common stock, with no sole voting or dispositive power reported for any of the filers.
T. Rowe Price Associates, Inc. reported beneficial ownership of common stock of Celldex Therapeutics Inc. on a Schedule 13G. The firm reported holding 4,686,187 shares of common stock, representing 6.0% of the class, with sole voting power over 4,683,226 shares and sole dispositive power over 4,686,187 shares. T. Rowe Price Associates stated that this report should not be construed as an admission that it is the beneficial owner of these securities.
Celldex Therapeutics reported a larger loss as it scales late-stage development of its lead antibody barzolvolimab. For the quarter ended June 30, 2026, net loss was $73.5 million (basic and diluted loss per share $0.94), versus $56.6 million a year earlier, driven by higher research and development spending. R&D expense rose to $67.5 million in the quarter and $140.5 million year‑to‑date, including $117.1 million devoted to the barzolvolimab/anti‑KIT program.
Liquidity strengthened after an April 2026 underwritten equity offering of 11.9 million shares that generated $323.8 million in net proceeds. At June 30, 2026, cash, cash equivalents and marketable securities totaled $717.6 million, with stockholders’ equity of $714.6 million. Management believes this balance will fund planned operations for at least twelve months from issuance of the financial statements.
Clinically, barzolvolimab is in global Phase 3 trials for chronic spontaneous urticaria with topline data expected in September/October 2026, and in Phase 3 for chronic inducible urticarias. A Phase 2 atopic dermatitis study is fully enrolled. After a Phase 2 miss, prurigo nodularis development is being discontinued. Bispecific candidate CDX‑622 completed a Phase 1 trial in healthy volunteers with supportive pharmacodynamic data and entered a proof‑of‑mechanism study in asthma.
Celldex Therapeutics, Inc. states that on August 6, 2026 it issued a press release announcing its financial results for the second quarter of 2026. The press release is provided as Exhibit 99.1 and is treated as information that is furnished, rather than filed, under the Exchange Act, limiting its treatment under Section 18 and other liability provisions.
The company also identifies Exhibit 104 as the cover page interactive data file embedded within the Inline XBRL document. Any future use of the press release in Securities Act or Exchange Act reports will occur only if specifically incorporated by reference.
Celldex Therapeutics, Inc. reported that Sam Martin, its Senior Vice President and Chief Financial Officer, has informed the company of his plans to retire effective on or about March 31, 2027. Martin joined Celldex in April 2009 and has served as Chief Financial Officer since July 2017.
The company has begun a search for a new Chief Financial Officer. To support continuity, Martin intends to continue serving as CFO through March 31, 2027, or until an appointed successor begins serving in that role, to help ensure a smooth transition of his responsibilities.
Celldex Therapeutics reported that SVP & Chief Commercial Officer Teri L. Lawver received an incentive stock option grant for 90,000 shares of common stock. The option has an exercise price of $34.09 per share and expires on June 25, 2036.
According to the grant terms, 25% of the option vests on June 25, 2027, with the remaining portion vesting in equal quarterly installments over the following 12 quarters. Following this award, Lawver holds options covering 90,000 shares, reflecting a compensation-related equity incentive rather than an open-market transaction.
Celldex Therapeutics SVP & General Counsel Freddy A. Jimenez received a grant of 93,000 incentive stock options to buy Celldex common stock. The options carry an exercise price of $34.09 per share and were granted under the company’s 2021 Omnibus Equity Incentive Plan.
According to the vesting schedule, 25% of the options vest on June 25, 2027, with the remaining options vesting in equal quarterly installments over the following 12 quarters. The options expire on June 25, 2036, and this award brings his reported derivative holdings in this grant to 93,000 options.
Celldex Therapeutics, Inc. reported that SVP and Chief Medical Officer Diane C. Young received a grant of 57,000 Incentive Stock Options to buy common stock.
The options have an exercise price of $34.09 per share, were granted under the company’s 2021 Omnibus Equity Incentive Plan, and represent compensation rather than an open-market purchase.
According to the filing, 25% of the award will vest on June 25, 2027, with the remaining options vesting in equal quarterly installments over the following 12 quarters, and the options will expire on June 25, 2036 if not exercised.